1. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
- Author
-
Ting Yang, Li Kong, Zhiping Zhang, Conglian Yang, Xiong Liu, Kexin Cui, and Qi Qiao
- Subjects
RBD, receptor-binding domains ,ARDS ,MSC, mesenchymal stem cells ,PLGA, poly(lactic-co-glycolic acid) ,MPO, myeloperoxidase ,NAC, N-acetylcysteine ,Review ,ICAM-1, intercellular adhesion molecule-1 ,TNF-α, tumor necrosis factor-α ,SDC1, syndecan-1 ,scFv, single chain variable fragments ,PC, phosphatidylcholine ,0302 clinical medicine ,EphA2, ephrin type-A receptor 2 ,BALF, bronchoalveolar lavage fluid ,PECAM-1, platelet-endothelial cell adhesion molecule ,Pathophysiologic feature ,PEG, poly(ethylene glycol) ,Acute lung injury ,cRGD, cyclic arginine glycine-D-aspartic acid ,Respiratory function ,General Pharmacology, Toxicology and Pharmaceutics ,IKK, IκB kinase ,PCB, poly(carboxybetaine) ,COVID-19, coronavirus disease 2019 ,HO-1, heme oxygenase-1 ,DPPC, dipalmitoylphosphatidylcholine ,0303 health sciences ,EPCs, endothelial progenitor cells ,Acute respiratory distress syndrome ,TPP, triphenylphosphonium cation ,RBC, red blood cells ,SP, surfactant protein ,EVs, extracellular vesicles ,MPMVECs, mouse pulmonary microvascular endothelial cells ,DOPE, phosphatidylethanolamine ,ECM, extracellular matrix ,CD, cyclodextrin ,Nanomedicine ,medicine.anatomical_structure ,H2O2, hydrogen peroxide ,030220 oncology & carcinogenesis ,Targeting strategy ,Drug delivery ,iNOS, inducible nitric oxide synthase ,LPS, lipopolysaccharide ,Esbp, E-selectin-binding peptide ,NETs, neutrophil extracellular traps ,medicine.medical_specialty ,PS-PEG, poly(styrene-b-ethylene glycol) ,PDE4, phosphodiesterase 4 ,NF-κB, nuclear factor-κB ,S1PLyase, sphingosine-1-phosphate lyase ,RM1-950 ,ACE2, angiotensin-converting enzyme 2 ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ,Siglec, sialic acid-binding immunoglobulin-like lectin ,GNP, peptide-gold nanoparticle ,Anti-inflammatory therapy ,Se, selenium ,03 medical and health sciences ,PDA, polydopamine ,ROS, reactive oxygen species ,Pharmacotherapy ,medicine ,NE, neutrophil elastase ,PEI, polyetherimide ,SARS, severe acute respiratory syndrome ,CLP, cecal ligation and perforation ,TLR, toll-like receptor ,Intensive care medicine ,EPR, enhanced permeability and retention ,FcgR, Fcγ receptor ,AM, alveolar macrophages ,ARDS, acute respiratory distress syndrome ,YSA, YSAYPDSVPMMS ,030304 developmental biology ,Lung ,PEVs, platelet-derived extracellular vesicles ,business.industry ,AEC II, alveolar type II epithelial cells ,MERS, Middle East respiratory syndrome ,Therapeutic effect ,COVID-19 ,DOTAP, 1-diolefin-3-trimethylaminopropane ,medicine.disease ,DOX, doxorubicin ,IL, interleukin ,rSPANb, anti-rat SP-A nanobody ,Middle East respiratory syndrome ,BSA, bovine serum albumin ,SORT, selective organ targeting ,Therapeutics. Pharmacology ,Nanocarriers ,ELVIS, Extravasation through Leaky Vasculature and subsequent Inflammatory cell-mediated Sequestration ,business - Abstract
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment., Graphical abstract Nanomedicine has demonstrated great potential in achieving specific targeting and amplifying therapeutic efficiency. This review focuses on the recent breakthroughs and targeting strategies to provide insights into nanomedicine for acute respiratory distress syndrome treatment.Image 1
- Published
- 2021